Corrigendum to ‘GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft’ [Canc. Lett. 330 (2013) 22–32](S0304383512006659)(10.1016/j.canlet.2012.11.018);GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft

Cancer Letters

Volumn 330, Issue 1, 2013, Pages 22-32

  Fu, Junsheng ^a   Rodova, Mariana ^a   Roy, Sanjit K ^a   Sharma, Jay ^b   Singh, Karan P ^c   Srivastava, Rakesh K ^a   Shankar, Sharmila ^a  

^a UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^b Celprogen   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

GANT 61; Gli transcription factor; Pancreatic cancer stem cells; Sonic hedgehog

Indexed keywords

CASPASE 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; GLI TRANSCRIPTION FACTOR INHIBITOR; MYC PROTEIN; NERVE CELL ADHESION MOLECULE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OCTAMER TRANSCRIPTION FACTOR 4; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN BCL 2; REGULATOR PROTEIN; SHORT HAIRPIN RNA; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; UNCLASSIFIED DRUG; UVOMORULIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STEM CELL; CELL GROWTH; CELL RENEWAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; HUMAN CELL; IL2R MOUSE; IN VITRO STUDY; METASTASIS; MOUSE STRAIN; NONHUMAN; NONOBESE DIABETIC MOUSE; PANCREAS CANCER; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RECEPTOR UPREGULATION; SCID MOUSE; SPHEROID CELL; TRANSCRIPTION REGULATION; TUMOR XENOGRAFT;

ERINACEIDAE; GASTROPODA; MUS;

EID: 84872861115     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2021.07.028     Document Type: Erratum

References (55)

1. Greaves M., Maley C.C. Clonal evolution in cancer. Nature 2012, 481:306-313.
2. Margueron R., Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature 2011, 469:343-349.
3. Biddle A., Mackenzie I.C. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012.
4. Visvader J.E. Cells of origin in cancer. Nature 2011, 469:314-322.
5. Ogden S.K., Ascano M., Stegman M.A., Robbins D.J. Regulation of Hedgehog signaling: a complex story. Biochem. Pharmacol. 2004, 67:805-814.
6. Yauch R.L., Gould S.E., Scales S.J., Tang T., Tian H., Ahn C.P., Marshall D., Fu L., Januario T., Kallop D., Nannini-Pepe M., Kotkow K., Marsters J.C., Rubin L.L., de Sauvage F.J. A paracrine requirement for Hedgehog signalling in cancer. Nature 2008, 455:406-410.
7. Ingham P.W., McMahon A.P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001, 15:3059-3087.
8. Ruiz I Altaba A. Therapeutic inhibition of Hedgehog-GLI signaling in cancer: epithelial, stromal, or stem cell targets?. Cancer Cell 2008, 14:281-283.
9. Ruiz I Altaba A. Gli proteins and Hedgehog signaling: development and cancer. Trends Genet. 1999, 15:418-425.
10. Dahmane N., Sanchez P., Gitton Y., Palma V., Sun T., Beyna M., Weiner H., Ruiz i Altaba A. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 2001, 128:5201-5212.
11. Gerber A.N., Wilson C.W., Li Y.J., Chuang P.T. The hedgehog regulated oncogenes Gli1 and Gli2 block myoblast differentiation by inhibiting myod-mediated transcriptional activation. Oncogene 2007, 26:1122-1136.
12. Kasper M., Regl G., Frischauf A.M., Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signalling. Eur. J. Cancer 2006, 42:437-445.
13. Lee J., Wu X., Pasca di Magliano M., Peters E.C., Wang Y., Hong J., Hebrok M., Ding S., Cho C.Y., Schultz P.G. A small-molecule antagonist of the Hedgehog signaling pathway. ChemBioChem 2007, 8:1916-1919.
14. Regl G., Kasper M., Schnidar H., Eichberger T., Neill G.W., Philpott M.P., Esterbauer H., Hauser-Kronberger C., Frischauf A.M., Aberger F. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res. 2004, 64:7724-7731.
15. Katoh Y., Katoh M. Integrative genomic analyses on GLI1: positive regulation of GLI1 by Hedgehog-GLI, tgfbeta-Smads, and RTK-PI3K-AKT signals, and negative regulation of GLI1 by Notch-CSL-HES/HEY, and GPCR-Gs-PKA signals. Int. J. Oncol. 2009, 35:187-192.
16. Hidalgo M., Maitra A. The hedgehog pathway and pancreatic cancer. New Engl. J. Med. 2009, 361:2094-2096.
17. Chen M.H., Wilson C.W., Li Y.J., Law K.K., Lu C.S., Gacayan R., Zhang X., Hui C.C., Chuang P.T. Cilium-independent regulation of Gli protein function by Sufu in Hedgehog signaling is evolutionarily conserved. Genes Dev. 2009, 23:1910-1928.
18. Williams J.A. Hedgehog signaling pathway as a target for therapeutic intervention in basal cell carcinoma. Drug News Perspect. 2003, 16:657-662.
19. Hutchin M.E., Kariapper M.S., Grachtchouk M., Wang A., Wei L., Cummings D., Liu J., Michael L.E., Glick A., Dlugosz A.A. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 2005, 19:214-223.
20. Grachtchouk M., Mo R., Yu S., Zhang X., Sasaki H., Hui C.C., Dlugosz A.A. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nat. Genet. 2000, 24:216-217.
21. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2:442-454.
22. Huber M.A., Kraut N., Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr. Opin. Cell Biol. 2005, 17:548-558.
23. Peinado H., Olmeda D., Cano A. Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?. Nat. Rev. Cancer 2007, 7:415-428.
24. Shankar S., Nall D., Tang S.N., Meeker D., Passarini J., Sharma J., Srivastava R.K. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011, 6:e16530.
25. Wiznerowicz M., Trono D. Conditional suppression of cellular genes: lentivirus vector-mediated drug-inducible RNA interference. J. Virol. 2003, 77:8957-8961.
26. Singh B.N., Fu J., Srivastava R.K., Shankar S. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One 2011, 6:e27306.
27. Xie J., Aszterbaum M., Zhang X., Bonifas J.M., Zachary C., Epstein E., McCormick F. A role of pdgfralpha in basal cell carcinoma proliferation. Proc. Natl. Acad. Sci. USA 2001, 98:9255-9259.
28. Tang S.N., Fu J., Nall D., Rodova M., Shankar S., Srivastava R.K. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int. J. Cancer 2011, 23:23.
29. Thiery J.P., Acloque H., Huang R.Y., Nieto M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
30. Iwatsuki M., Mimori K., Fukagawa T., Ishii H., Yokobori T., Sasako M., Baba H., Mori M. The clinical significance of vimentin-expressing gastric cancer cells in bone marrow. Ann. Surg. Oncol. 2010, 17:2526-2533.
31. Monteiro J., Fodde R. Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur. J. Cancer 2010, 46:1198-1203.
32. Merchant J.L. Hedgehog signalling in gut development, physiology and cancer. J. Physiol. 2012, 590:421-432.
33. Vogt A., Chuang P.T., Hebert J., Hwang J., Lu Y., Kopelovich L., Athar M., Bickers D.R., Epstein E.H. Immunoprevention of basal cell carcinomas with recombinant Hedgehog-interacting protein. J. Exp. Med. 2004, 199:753-761.
34. Ward R.J., Lee L., Graham K., Satkunendran T., Yoshikawa K., Ling E., Harper L., Austin R., Nieuwenhuis E., Clarke I.D., Hui C.C., Dirks P.B. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009, 69:4682-4690.
35. Thiyagarajan S., Bhatia N., Reagan-Shaw S., Cozma D., Thomas-Tikhonenko A., Ahmad N., Spiegelman V.S. Role of GLI2 transcription factor in growth and tumorigenicity of prostate cells. Cancer Res. 2007, 67:10642-10646.
36. Mazumdar T., DeVecchio J., Shi T., Jones J., Agyeman A., Houghton J.A. Hedgehog signaling drives cellular survival in human colon carcinoma cells. Cancer Res. 2011, 71:1092-1102.
37. Ruiz i Altaba A., Stecca B., Sanchez P. Hedgehog-Gli signaling in brain tumors: stem cells and paradevelopmental programs in cancer. Cancer Lett. 2004, 204:145-157.
38. Ecke I., Petry F., Rosenberger A., Tauber S., Monkemeyer S., Hess I., Dullin C., Kimmina S., Pirngruber J., Johnsen S.A., Uhmann A., Nitzki F., Wojnowski L., Schulz-Schaeffer W., Witt O., Hahn H. Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice. Cancer Res. 2009, 69:887-895.
39. Vorechovsky I., Benediktsson K.P., Toftgard R. The Patched/Hedgehog/Smoothened signalling pathway in human breast cancer: no evidence for H133Y SHH, PTCH and SMO mutations. Eur. J. Cancer 1999, 35:711-713.
40. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., Hong S.M., Fu B., Lin M.T., Calhoun E.S., Kamiyama M., Walter K., Nikolskaya T., Nikolsky Y., Hartigan J., Smith D.R., Hidalgo M., Leach S.D., Klein A.P., Jaffee E.M., Goggins M., Maitra A., Iacobuzio-Donahue C., Eshleman J.R., Kern S.E., Hruban R.H., Karchin R., Papadopoulos N., Parmigiani G., Vogelstein B., Velculescu V.E., Kinzler K.W. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
41. Olive K.P., Jacobetz M.A., Davidson C.J., Gopinathan A., McIntyre D., Honess D., Madhu B., Goldgraben M.A., Caldwell M.E., Allard D., Frese K.K., Denicola G., Feig C., Combs C., Winter S.P., Ireland-Zecchini H., Reichelt S., Howat W.J., Chang A., Dhara M., Wang L., Ruckert F., Grutzmann R., Pilarsky C., Izeradjene K., Hingorani S.R., Huang P., Davies S.E., Plunkett W., Egorin M., Hruban R.H., Whitebread N., McGovern K., Adams J., Iacobuzio-Donahue C., Griffiths J., Tuveson D.A. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009, 324:1457-1461.
42. Von Hoff D.D., LoRusso P.M., Rudin C.M., Reddy J.C., Yauch R.L., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Mackey H.M., Lum B.L., Darbonne W.C., Marsters J.C., de Sauvage F.J., Low J.A. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. New Engl. J. Med. 2009, 361:1164-1172.
43. Lorusso P.M., Rudin C.M., Reddy J.C., Tibes R., Weiss G.J., Borad M.J., Hann C.L., Brahmer J.R., Chang I., Darbonne W.C., Graham R.A., Zerivitz K.L., Low J.A., Von Hoff D.D. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 2011, 17:2502-2511.
44. Varnat F., Duquet A., Malerba M., Zbinden M., Mas C., Gervaz P., Ruiz i Altaba A. Human colon cancer epithelial cells harbour active HEDGEHOG-GLI signalling that is essential for tumour growth, recurrence, metastasis and stem cell survival and expansion. EMBO Mol. Med. 2009, 1:338-351.
45. Johnson R.W., Nguyen M.P., Padalecki S.S., Grubbs B.G., Merkel A.R., Oyajobi B.O., Matrisian L.M., Mundy G.R., Sterling J.A. TGF-beta promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling. Cancer Res. 2011, 71:822-831.
46. Lauth M., Bergstrom A., Shimokawa T., Toftgard R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA 2007, 104:8455-8460.
47. Dierks C., Grbic J., Zirlik K., Beigi R., Englund N.P., Guo G.R., Veelken H., Engelhardt M., Mertelsmann R., Kelleher J.F., Schultz P., Warmuth M. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat. Med. 2007, 13:944-951.
48. Tian H., Callahan C.A., DuPree K.J., Darbonne W.C., Ahn C.P., Scales S.J., de Sauvage F.J. Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis. Proc. Natl. Acad. Sci. USA 2009, 106:4254-4259.
49. Feldmann G., Fendrich V., McGovern K., Bedja D., Bisht S., Alvarez H., Koorstra J.B., Habbe N., Karikari C., Mullendore M., Gabrielson K.L., Sharma R., Matsui W., Maitra A. An orally bioavailable small-molecule inhibitor of Hedgehog signaling inhibits tumor initiation and metastasis in pancreatic cancer. Mol. Cancer Ther. 2008, 7:2725-2735.
50. Hashimoto-Torii K., Motoyama J., Hui C.C., Kuroiwa A., Nakafuku M., Shimamura K. Differential activities of Sonic Hedgehog mediated by Gli transcription factors define distinct neuronal subtypes in the dorsal thalamus. Mech. Dev. 2003, 120:1097-1111.
51. Nolan-Stevaux O., Lau J., Truitt M.L., Chu G.C., Hebrok M., Fernandez-Zapico M.E., Hanahan D. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009, 23:24-36.
52. Marchese R., Muleti A., Pasqualetti P., Bucci B., Stigliano A., Brunetti E., De Angelis M., Mazzoni G., Tocchi A., Brozzetti S. Low correspondence between K-ras mutations in pancreatic cancer tissue and detection of K-ras mutations in circulating DNA. Pancreas 2006, 32:171-177.
53. Lauth M., Toftgard R. The Hedgehog pathway as a drug target in cancer therapy. Curr. Opin. Investig. Drugs 2007, 8:457-461.
54. Srivastava R.K. TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001, 3:535-546.
55. Li D., Xie K., Wolff R., Abbruzzese J.L. Pancreatic cancer. Lancet 2004, 363:1049-1057.